Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:12:27 EDT Tue 27 Oct 2026
Enter Symbol
or Name
USA
CA



Q:CRMD - CORMEDIX INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CRMD - Q0.17.09·8.350.48.00+0.060.81,002.37,6468,3757.91  8.11  7.8013.02  6.12518:34:46Oct 1915 min RT 2¢

Recent Trades - Last 10 of 8375
Time ETExPriceChangeVolume
18:34:46Q7.84-0.101
16:57:38Q8.05080.110850
16:50:26Q8.100.161
16:41:52Q7.92-0.0210
16:10:05Q8.000.061
16:10:05Q8.000.061
16:04:00Q8.000.061
16:04:00Q8.000.061
16:04:00Q8.000.061
16:01:23Q8.000.06163

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-10-19 07:30U:CRMDNews ReleaseCormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo(TM) (Rezafungin) for Prophylaxis of Invasive Fungal Diseases
2026-10-15 07:30U:CRMDNews ReleaseActinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
2026-09-01 08:30U:CRMDNews ReleaseCorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
2026-08-13 07:30U:CRMDNews ReleaseCormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-29 08:30U:CRMDNews ReleaseCorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026
2026-06-08 08:30U:CRMDNews ReleaseU.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin(TM) Patent Litigation
2026-05-15 08:30U:CRMDNews ReleaseCormedix Therapeutics to Participate in two Upcoming Investor Conferences
2026-05-14 07:30U:CRMDNews ReleaseCormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-05 08:30U:CRMDNews ReleaseCorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
2026-04-27 07:30U:CRMDNews ReleaseCorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO(TM) for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
2026-04-07 08:30U:CRMDNews ReleaseCorMedix to Participate in Needham Virtual Healthcare Conference
2026-03-05 07:30U:CRMDNews ReleaseCorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-03-02 08:30U:CRMDNews ReleaseCorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026
2026-02-12 08:30U:CRMDNews ReleaseCorMedix to Participate in Upcoming Investor Conferences
2026-02-02 08:30U:CRMDNews ReleaseCorMedix Therapeutics Announces Share Repurchase Program
2026-01-29 08:30U:CRMDNews ReleaseCorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026
2026-01-09 08:30U:CRMDNews ReleaseCorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
2026-01-08 08:05U:CRMDNews ReleaseCorMedix Therapeutics Announces Leadership and Board Updates
2026-01-08 08:00U:CRMDNews ReleaseCorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates
2025-12-18 08:00U:CRMDNews ReleaseCorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath